Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?
Fiche publication
Date publication
janvier 2024
Journal
Frontiers in medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr IMPERIALE Alessio, Dr POROT Clémence
Tous les auteurs :
Ouvrard E, Kaseb A, Poterszman N, Porot C, Somme F, Imperiale A
Lien Pubmed
Résumé
Accurate detection and reliable assessment of therapeutic responses in bone metastases are imperative for guiding treatment decisions, preserving quality of life, and ultimately enhancing overall survival. Nuclear imaging has historically played a pivotal role in this realm, offering a diverse range of radiotracers and imaging modalities. While the conventional bone scan using Tc marked bisphosphonates has remained widely utilized, its diagnostic performance is hindered by certain limitations. Positron emission tomography, particularly when coupled with computed tomography, provides improved spatial resolution and diagnostic performance with various pathology-specific radiotracers. This review aims to evaluate the performance of different nuclear imaging modalities in clinical practice for detecting and monitoring the therapeutic responses in bone metastases of diverse origins, addressing their limitations and implications for image interpretation.
Mots clés
18 F-FDG, 18 F-fluorocholine, 18F-DOPA, 18F-NaF?, 68Ga-DOTA, 99mTc, bone metastases, bone scan
Référence
Front Med (Lausanne). 2024 01 15;10:1320574